Orexigen(R) Therapeutics to Speak at Barclays Capital 2010 Global Healthcare Conference

Friday, March 19, 2010 General News J E 4

SAN DIEGO, March 18 Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at Barclays Capital 2010 Global Healthcare Conference.

The details are as follows:

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials. The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at

Date: Wednesday, March 24, 2010 Time: 3:45 - 4:10 PM Eastern Location: Loews Miami Hotel, Florida Speaker: Graham Cooper, Chief Financial Officer

SOURCE Orexigen Therapeutics, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Providence's LogistiCare Subsidiary Receives Notic...
Immucor to Announce Fiscal Third Quarter Financial...